Ayahuasca Depression Treatment: What the First Randomized Trial Showed

What Is Ayahuasca, and Why Would It Affect Depression?

Ayahuasca is a brew traditionally prepared in the Amazon basin from two plants. One, Psychotria viridis, contains DMT, a compound that acts on the same serotonin receptors as psilocybin and LSD. The other, Banisteriopsis caapi, contains harmala alkaloids that block an enzyme in the gut which would otherwise break DMT down before it reached the brain. On its own, swallowed DMT does nothing. Combined with the vine, it becomes orally active, and the experience typically lasts four to six hours.

That pharmacological detail matters for anyone evaluating ayahuasca depression treatment, because those same harmala alkaloids are monoamine oxidase inhibitors. MAOIs interact dangerously with a long list of medications, including most antidepressants. This is not a footnote. It is the single most important safety fact about this medicine, and we will return to it.

The rationale for studying ayahuasca in depression rests on what researchers observed with other serotonergic psychedelics. Brain imaging work from the same Brazilian group showed that ayahuasca reduces activity in the default mode network, a set of brain regions that tends to be overactive in depression and is associated with rumination and rigid self-focused thinking. The theory is that quieting that network briefly opens a window in which entrenched depressive patterns become more workable. That is a plausible mechanism, not a proven one.

What Did the First Randomized Clinical Trial Actually Find?

The study most often cited is Palhano-Fontes and colleagues, published in Psychological Medicine in 2019 and conducted at the Federal University of Rio Grande do Norte in Natal, Brazil. The authors described it as the first controlled trial to test a psychedelic substance in treatment-resistant depression.

Here is what we know so far. Twenty-nine patients with treatment-resistant depression were randomized in a parallel-arm, double-blind design to receive either a single dose of ayahuasca or a placebo. The placebo was not an inert sugar pill. It was a bitter, brownish liquid designed to mimic the taste and appearance of the brew, which matters because a completely tasteless placebo would fool nobody. Depression severity was tracked using two standard clinician-rated scales, the Montgomery-Åsberg Depression Rating Scale and the Hamilton Depression Rating Scale.

The ayahuasca group showed significantly lower depression scores than the placebo group at one day, two days, and seven days after dosing. The between-group effect sizes grew over that week, from a Cohen’s d of 0.84 on day one to 1.49 on day seven. For a non-statistician, an effect size that large is unusual in depression research. Most conventional antidepressants produce between-group effects far smaller than this against placebo.

Response rates, meaning a clinically meaningful drop in symptoms, were 64 percent in the ayahuasca group versus 27 percent in the placebo group at day seven. Remission rates, meaning symptoms fell to a level no longer consistent with active depression, were 36 percent versus 7 percent, a difference that fell just short of statistical significance.

This is where things get more nuanced. That 27 percent placebo response is high, and the authors noted that patients in the trial stayed in an unusually supportive and comfortable environment, and suggested that part of the elevated placebo effect might reflect the care itself rather than anything in the cup. That observation cuts both ways. It complicates the interpretation of the numbers, and it also tells you something important about how much the setting contributes to any outcome in this field.

How Strong Is This Evidence, Really?

We classify ayahuasca for depression as Tier 2 evidence: one small randomized controlled trial with a clear positive signal, supported by earlier uncontrolled work, but not yet replicated at scale.

The limitations are worth stating directly.

Sample size. Twenty-nine patients is small. Small trials tend to overestimate effect sizes, and the confidence intervals around those numbers are wide.

Follow-up duration. The primary outcomes stopped at day seven. We do not know from this trial whether the benefit persisted at one month, three months, or a year. The psilocybin literature suggests durability is possible, but suggestion is not evidence.

Blinding. Anyone who receives a full dose of a powerful psychedelic generally knows they received it. This problem affects every psychedelic trial, and it means some portion of any measured benefit may reflect expectation rather than pharmacology.

Single site. The work comes from one research group in one country. Independent replication is the standard that separates an interesting finding from an established one, and it has not yet happened at scale for ayahuasca.

The supporting evidence is real but thinner than the headline suggests. An earlier open-label trial by Sanches and colleagues gave a single dose of ayahuasca to 17 inpatients with recurrent depression and tracked them for 21 days. Significant symptom reduction appeared within hours of dosing and remained measurable through the three-week mark. Open-label means everyone knew what they were taking, so the finding is a signal, not proof.

What we can say with confidence is this: something is happening, it happens fast, and it is unlikely to be entirely placebo. What we cannot say is how long it lasts, who it works for, or how it compares to the alternatives.

How Does Ayahuasca Compare to Psilocybin and Ketamine for Depression?

Ayahuasca is the least studied of the three, by a wide margin.

Ketamine has the largest and most mature evidence base, with FDA approval for a nasal formulation in treatment-resistant depression and legal availability throughout the United States. Psilocybin has multiple randomized controlled trials, larger samples, longer follow-up, and regulated access in Oregon and Colorado. Ayahuasca has one small randomized trial and no regulated therapeutic pathway anywhere in the United States.

For a more complete picture of how these medicines compare across evidence quality, duration, and access, our comparison of which psychedelic works best for depression covers each one in detail. For background on the brew itself, its risks, and what a session involves, see our complete guide to ayahuasca.

What Are the Real Risks of Ayahuasca for Someone with Depression?

This section deserves more weight than the efficacy numbers, particularly for a reader who is currently depressed and currently medicated.

The MAOI interaction. Because the vine contains monoamine oxidase inhibitors, combining ayahuasca with an SSRI, SNRI, MAOI, tramadol, certain migraine medications, or a range of other drugs can produce serotonin syndrome, a condition that can be fatal. Most people seeking ayahuasca for depression are, by definition, already on an antidepressant. This is the central danger, and it is not theoretical. Anyone considering ayahuasca must have a medically supervised taper plan, and tapering an antidepressant while depressed carries its own significant risks. Our overview of SSRIs and psychedelic therapy covers this interaction in depth.

Cardiovascular strain. Ayahuasca raises heart rate and blood pressure. Pre-existing cardiac conditions are a genuine contraindication.

Physical intensity. Vomiting is common and is culturally framed as part of the process in traditional contexts. It is still vomiting, and for someone in a fragile physical state it is not trivial.

Psychiatric risk. A personal or family history of psychosis or bipolar disorder is a contraindication for serotonergic psychedelics generally. Our guide to who should not pursue psychedelic therapy covers the full list.

Setting risk. Ayahuasca has no legal therapeutic pathway in the United States outside of a narrow religious exemption for two churches. In practice this means most people access it abroad, in retreat settings with no licensing standard, no medical screening requirement, and no consistent accountability. The quality range is enormous. Some retreats are staffed by experienced facilitators with medical support on site. Others are not, and the trial that produced the encouraging numbers above was conducted in a hospital with physicians present.

What Should You Do With This Information?

If you have treatment-resistant depression and you are reading this because you are running out of options, the honest framing is that ayahuasca is a serious candidate for future medicine and a poor candidate for a decision made this month.

The medicine with the best combination of evidence, legality, and medical supervision available to you right now is ketamine, which is accessible under physician care in every state. Psilocybin is the next tier, with regulated access in Oregon and Colorado. Ayahuasca remains a legitimate research subject and a poorly regulated consumer experience, and those two things should not be confused with each other.

If you are still drawn to ayahuasca specifically, the questions that matter are medical, not spiritual. What medications are you on, and can they be safely tapered under supervision? What is your cardiac history? Who is screening you, what are their credentials, and what happens if something goes wrong at hour three?

Those are the questions a good guide asks first. If nobody is asking them, that tells you what you need to know about where you are.